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Abstract
Background: Comprehensive, longitudinal field studies that monitor both disease and vector populations for dengue
viruses are urgently needed as a pre-requisite for developing locally adaptable prevention programs or to appropriately test
and license new vaccines.
Methodology and Principal Findings: We report the results from such a study spanning 5 years in the Amazonian city of
Iquitos, Peru where DENV infection was monitored serologically among ,2,400 members of a neighborhood-based cohort
and through school-based absenteeism surveillance for active febrile illness among a subset of this cohort. At baseline, 80%
of the study population had DENV antibodies, seroprevalence increased with age, and significant geographic variation was
observed, with neighborhood-specific age-adjusted rates ranging from 67.1 to 89.9%. During the first 15 months, when
DENV-1 and DENV-2 were co-circulating, population-based incidence rates ranged from 2–3 infections/100 person-years (p-
years). The introduction of DENV-3 during the last half of 2001 was characterized by 3 distinct periods: amplification over at
least 5–6 months, replacement of previously circulating serotypes, and epidemic transmission when incidence peaked at 89
infections/100 p-years.
Conclusions/Significance: Neighborhood-specific baseline seroprevalence rates were not predictive of geographic
incidence patterns prior to the DENV-3 introduction, but were closely mirrored during the invasion of this serotype.
Transmission varied geographically, with peak incidence occurring at different times among the 8 geographic zones in
,16 km2 of the city. The lag from novel serotype introduction to epidemic transmission and knowledge of spatially explicit
areas of elevated risk should be considered for more effective application of limited resources for dengue prevention.
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Introduction
Dengue viruses (DENV) are major re-emerging pathogens that
have increased geographically from only 9 countries 60 years ago
to more than 100 today. An estimated 2.5–3.0 billion people
worldwide are at risk, with 50–100 million cases of dengue fever
(DF) and 250,000–500,000 of the more severe dengue hemor-
rhagic fever (DHF) and dengue shock syndrome (DSS) each year.
Incidence of severe disease (DHF/DSS) has been increasing
consistently since the 1950’s [1,2,3,4,5].
DENV exists as four closely-related, antigenically distinct single-
stranded RNA viruses (DENV-1, DENV-2, DENV-3 and DENV-
4) in the genus Flavivirus, family Flaviridae. Immunity induced by
infection with one serotype is protective and affords transient
cross-protection against the other serotypes; hence sequential
infections with different serotypes are possible. The etiology of
serious illness is not completely understood, but secondary
infection and/or variation in virus virulence have often been
implicated [1,4,5,6,7,8].
Without a vaccine, dengue prevention relies on virological
surveillance and vector control. Mounting evidence indicates that
accounting for variation in the ecology and epidemiology of
dengue will be important for development of more effective,
locally adapted control programs [9,10]. Such programs, along
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with future phase III vaccine trials, will require an improved
understanding of region-specific transmission dynamics. This
information is best obtained from comprehensive, longitudinal
field studies designed to provide a detailed understanding of
fundamental processes in virus transmission, epidemiology and
disease control [9].
In Latin America, successful control efforts that ended in the
1960’s were followed by reinvasion of the mosquito vector Aedes
aegypti and the emergence of dengue as a leading public health
problem throughout the continent. Wide-spread urbanization
contributed to spread of the vector, creating conditions that
enhanced DENV transmission. This is exemplified by numerous
recent and dramatic regional outbreaks. Here we report results
from longitudinal studies in Iquitos, Peru, an Amazonian city with
a history of dengue virus transmission that has been well
documented by the US Naval Medical Research Center
Detachment (NMRCD) since the early 1990’s, when DENV was
presumably reintroduced into Peru [11]. Iquitos experienced
epidemics of febrile disease caused by sequential invasions of
DENV: DENV-1 in 1990—1991, an American strain of DENV-2
in 1995 [7,12], DENV-3 in 2001 [13], an Asian strain of DENV-2
in 2002, and DENV-4 in 2008 [14].
The long-term goal of our research in Iquitos was to acquire a
detailed understanding of dynamics in DENV transmission and
their relationship to entomological parameters that will inform
vector control programs and improve disease prevention. Our
approach was to monitor virus transmission and Ae. aegypti
population densities simultaneously in the homes and neighbor-
hoods of a longitudinal cohort representing 20% of the most
populated areas of the city. Ae. aegypti abundance and production
patterns were previously described [15,16,17,18]. Herein, we
examine spatial and temporal patterns of transmission dynamics
for 3 DENV serotypes before and during the invasion of a locally
novel virus. Our results are based on a prospective cohort study
conducted between 1999–2005, during which time there was
active transmission of DENV-1 and DENV-2 and invasion of
DENV-3, which caused a significant epidemic of febrile disease.
Materials and Methods
Human Use Statement
The study protocol was approved by the University of
California, Davis (Protocol 2220210788-4(994054), Instituto
Nacional de Salud, and Naval Medical Research Center (Protocol
#NMRCD.2001.0008 [DoD 31574]) Institutional Review Boards
in compliance with all Federal regulations governing the
protection of human subjects.
Study Area
Our study was conducted in Iquitos, an urban community
located in the Amazon Basin of northeastern Peru (73.2uW, 3.7uS,
120 m above sea level) in the Department of Loreto. The Amazon,
Nanay, and Itaya Rivers surround it on 3 sides. The population in
the city has grown since its last published census of 350,000 people
[19]. The more common industries are small business, fishing, oil,
lumber, tourism and agriculture. The climate is tropical, with an
average daily temperature of 25.8uC (average minimum 21.9uC
and maximum 32.4uC) and an average annual precipitation of
3.4 meters (range 2.7—4.4 meters) during our study. Precipitation
occurs throughout the year, on about half the days (51.6%).
Iquitos is described in detail in earlier reports [7,12,15,16,17,18].
Iquitos is comprised of 4 districts: San Juan, Maynas, and
Punchana running from South to North and Belen on the East
(See Figure 1 in [17]). We restricted our study to an area of
<16 km2 in the districts of Maynas, Punchana and small portions
of Belen and San Juan, which we divided into 8 geographic zones
(described in detail in [17]) based on known neighborhoods served
by distinct health centers. In brief, the 3 most northern zones –
Punchana (PU), Maynas (MY), and San Antonio (SA) – and the 5
remaining southern zones – Putumayo (PT), Iquitos (IQ), Morona
Cocha (MC), Bagazan (BG) and Tupac Amaru (TA) – belong to
the districts of Punchana and Maynas, respectively; each has its
own local government and services. The zones of Tupac Amaru
(TA), Bagazan (BG), and Putumayo (PT) each have areas where
houses are flooded seasonally.
Study Design
We monitored a cohort of ,2,400 study participants longitu-
dinally from January 1999 through August 2003 at ,6-month
intervals for serological evidence of DENV infection. In addition,
serological monitoring continued until February 2005 in a subset
of school age cohort participants who were also monitored for
active dengue disease based on attendance at school (see sub-
section febrile surveillance below). To obtain a geographically
and temporally stratified sample of study participants, each of the
8 study zones was sub-divided into approximately 5 equal areas.
Three blocks from each area were randomly selected for a total of
15 sample blocks in each zone. Recruitment focused on school-
aged children (between 5 and 20 years). To obtain a more
stratified cross-section of the population, participation was also
offered to other members of the household after a school-aged
participant was enrolled. If the residents agreed to participate, the
consent and assent forms were signed before samples were
obtained. Written informed consent was obtained from partici-
pants older than 17 years, and from parents of participants
younger than 18. In addition, assent was obtained from
participants 8–17 years of age. If participants were unable to
read and sign the consent form, oral consent was obtained and
documented in the presence of a witness. Fifty school-aged
Author Summary
To develop prevention (including vaccines) and control
programs for dengue fever, a significant mosquito-borne
disease in the tropics, there is an urgent need for
comprehensive long term field epidemiological studies.
We report results from a study that monitored ,2,400
school children and some adult family members for
dengue infection at 6 month intervals from 1999 to
2005, in the Amazonian city of Iquitos, Peru. At enrollment,
,80% of the participants had a previous infection with
DENV serotypes 1 and 2 or both. During the first 15
months, about 3 new infections for every 100 participants
were observed among the study participants. In 2001,
DENV-3, a serotype not previously observed in the region,
invaded Iquitos in a process characterized by 3 distinct
periods: amplification over at least a 5–6 month period,
replacement of previously circulating serotypes, and
epidemic transmission when incidence peaked. Incidence
patterns of new infections were geographically distinct
from baseline prevalence rates prior to arrival of DENV-3,
but closely mirrored them during the invasion. DENV
transmission varied geographically corresponding to
elevated mosquito densities. The invasion of a novel
serotype is often characterized by 5–6 months of silent
transmission before traditional surveillance programs
detect the virus. This article sets the stage for subsequent
publications on dengue epidemiology.
Dengue Transmission in Iquitos
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participants and 10 family members older than 20 were recruited
from each zone each month, repeating the process each month
until a base cohort of 2,400 individuals was obtained (Table S1;
see Figure 1 in [20]).
After the base cohort was established, follow-up visits for
individual participants were carried out at approximately 6-month
intervals. Participants were considered lost to follow up after a full
year had passed since their previous blood draw, despite repeated
attempts to locate the participant, or if there was a verifiable
reason for dropping them from the study (direct request from the
participant, movement from the study area, or death). New
participants were enrolled to replace those lost to follow up, with
preference toward people from the same geographic zones as those
lost, in order to maintain an active cohort of ,2,400 individuals.
In some cases participants would re-enroll in the study after
returning from an extended trip or regaining interest in the study.
In June 2000, a subset of 1,100 cohort members (ages 5—20)
who were attending morning sessions at one of the 29 participating
public schools in the city were recruited for surveillance of febrile
disease [20]. In addition to participating in the longitudinal
components of the study (6-month blood samples and entomo-
logical surveys) this sub-population was monitored for symptom-
atic DENV cases. Phlebotomists visited schools daily, checked
attendance, and visited the homes of participating absentees. If the
absence was caused by febrile illness, acute and convalescent blood
samples were obtained and daily medical exams carried out for
each participant. During school vacation, children were visited
weekly at their homes. New participants were enrolled to replace
those who had dropped out of school, graduated, or changed
schools. After entomological surveillance ended in August 2003,
the school surveillance study continued for participants who
remained in monitored schools. At the beginning of the 2004
school year, additional participants were recruited from previously
enrolled families (siblings or other relatives) or from households
participating in a community-based cohort study [20]. Monitoring
of absences ended in December 2004, and final blood samples
were obtained from children up to March 2005. Clinical aspects of
this study will be reported in subsequent publications.
Blood sample collection. Blood samples were obtained by
venipuncture or fingerstick using standard aseptic techniques,
using one 3 mL VacutainerH collection tube (red top) without
anticoagulant per participant or three 0.25 mL sterile capillary
tubes that were expressed into screw-top plastic vials. All samples
were taken at the home of the participant, labeled, and stored in
small portable ice chests until they were transported to our field
laboratory within 4 hrs. Blood samples were centrifuged for
10 minutes at 3,000 rpm at 4uC, and sera were then transferred to
cryovials and stored at 270uC, until transported on dry ice to the
NMRCD laboratory facilities in Lima for serological testing for
DENV antibodies.
Plaque Reduction Neutralization Tests (PRNT)
All blood samples from the longitudinal arm of the study were
assayed by plaque reduction neutralization test (PRNT) using 70%
reduction for the cut-offs (PRNT70). PRNT70 were carried out at
final serum dilutions of 1:60 and 1:120 (after addition of virus) for
Figure 1. Participant enrollment and lost to follow up (LTF) for longitudinal cohort (LC) and subset school-based febrile
surveillance (FS) studies carried out between January 1999 and February 2005. All participants enrolled in LC provided blood samples
taken at ,6-month intervals that were tested by PRNT for DENV NtAbs to identify seroconversions. Entomological surveys were carried out through
August 2003. Participation in FS included the LC activities plus absence monitoring in school initiated in June 2000. After August 2003, only FS
participants continued to be monitored serologically. Absence monitoring in schools continued through December 2004. Participants recruited after
August 2003 provided serological samples for PRNT testing and all students finishing the study provided a final serological sample between
December 2004–February 2005. Inset: The distribution of the number of blood samples taken at intervals from individual participants.
doi:10.1371/journal.pntd.0000670.g001
Dengue Transmission in Iquitos
www.plosntds.org 3 May 2010 | Volume 4 | Issue 5 | e670
DENV-1 and DENV-2 and 1:30 and 1:60 for DENV-3. For
DENV-2 linear regression models were fit to estimate the percent
reduction at cut-off dilution of 1:80, whereas a cutoff dilution of 1:60
was used for DENV-1 and DENV-3. Because DENV-3 was not
detected in Iquitos until December 2001, routine screening of
samples for DENV-3 neutralizing antibody (NtAb) was not initiated
for sera collected until after January 2002. For participants who may
have seroconverted to DENV-3 before 2002, prior samples were
tested for DENV-3 sequentially until a sample negative for DENV-3
was observed. DENV-4 circulation was not detected in Iquitos
between 1993 through the end of this cohort study [14]. We did not,
therefore, test for DENV-4 antibody.
PRNTs were performed as described by Sangkawibha [21] and
Graham [22], with a modified protocol for semi-micro methods
with baby hamster kidney (BHK-21) cells (clone 15) in 12 or 24
well plates [23]. Modifications are described in detail by Kochel et
al. [8] and Comach et al. [24]. Briefly, 0.2 mL of diluted test sera
were mixed with 0.2 mL diluted media (Earle’s minimal essential
medium [E-MEM], 2% fetal bovine serum [FBS], and antibiotic/
antimycotic) containing 40–80 PFU of assay virus and then
incubated at 4uC for 15 hours. Unless otherwise stated, DENV
strains utilized in the PRNT were two viruses isolated in Thailand
in 1974 from DHF cases [25], DENV-1 16007 and DENV-2
16681, as well as a 2001 Peruvian isolate (from a DF case) of
DENV-3, IQD1728. Prior to use in the assay, viruses were
amplified in Ae. albopictus C6/36 cell culture and aliquots frozen at
270uC to ensure consistency in testing throughout the study. Sera
were heat-inactivated at 56uC for 30 minutes before the PRNT. In
triplicate, 0.1 mL of virus-serum mixture (dengue-1: 16007;
dengue-2: 16681; dengue-3: IQT1728) was added to 0.5 mL
media containing 1.56105 BHK21 cells and then added to a well
of a 24 well tissue culture plate and incubated at 37uC with 5%
CO2 for 3 hrs. The cells were then overlaid with 0.5 mL of overlay
media (0.6% carboxymethyl Cellulose, MEM w/o phenol Red,
10% FBS, 0.075% NaHCO3 and antibiotic/antimycotic) and
incubated at 37uC with 5% CO2 for 5 days. The media was
removed, and the cells rinsed with H2O and stained with 0.5 mL/
well stain solution (0.1% (w/v) Naphthol Blue Black, 1.36% (w/v)
Sodium Acetate, and 6% (v/v) Glacial Acetic Acid) for 30 min.
Stain was removed and plaques were counted. Results were
expressed as the serum dilution, determined by linear regression
analysis, that reduced the number of plaques by 70% compared to
that of normal human serum at the same dilution. Positive and
negative human control sera were included with every batch of
sera tested. Cutoff values, established based on the ability of the
assay to maximize serotype sensitivity and specificity, were 1:60 for
DENV-1 and DENV-3 and 1:80 for DENV-2 (Minnick SL,
unpublished data).
Interpretation of PRNT results. PRNT is the most specific
serological test for dengue infections, but a number of factors
influence its sensitivity and specificity, including cross-reactions
among antibodies to different dengue serotypes [8,26,27] (Minnick
et al. unpublished data). To account for potential errors in the
interpretation of PRNTs for a single blood sample, we determined
seroconversions (SC) by considering serological profiles derived
from the full sequence of blood samples for each participant. The
following criteria were used to identify serotype-specific
seroconversions. A seroconversion was scored when the percent
increase in reduction between a negative sample and a subsequent
sample was greater than 20% and results from later samples were
consistently positive (e.g., ---+++). When subsequent PRNT results
were not consistent, a seroconversion was not scored. These were
considered false-positives (FP; e.g., --+--). Isolated reversions were
considered false negatives (FN; e.g., --++-++). False-positive/false-
negative rates were used to calculate correction factors to estimate
the true number of seroconversions among participants who
showed indication of seroconversion in the final sample of a series
(e.g., ---+) for incidence rate estimates. Correction factors (Table 1)
were calculated as the number of true-positives (TP) over the total
number of apparent seroconversions, TP/(TP + FP).
Febrile Surveillance
If a study participant was observed to have a febrile illness
during school-based surveillance activities, acute and convalescent
blood samples were collected. Acute-phase serum samples were
tested for DENV infection either by virus isolation in cell culture
or by detection of viral RNA by reverse transcription polymerase
chain reaction (RT-PCR). Both acute- and convalescent-phase
samples were screened for anti-DENV IgM antibody by IgM-
capture enzyme-linked immunosorbant assay (ELISA). In addi-
tion, a subset of acute and convalescent samples (those collected
prior to 2002 and a subset of those collected during 2004) was
screened for anti-DENV IgG antibodies by ELISA. Febrile
episodes were classified as DENV infections based on the isolation
of virus, RT-PCR, IgM serology (elevated IgM antibody titers
[$1:100] in the acute sample, convalescent sample, or both), or
IgG antibody serology (four-fold rise in titers between acute and
convalescent samples). Infections identified by viral detection, IgM
Table 1. Correction factors for estimating true number of
seroconversions for participants who have evidence of
seroconversion in a single post-conversion sample.
Profile FALSE+ TRUE+ TOTAL Correction Factor
N-D1 75 28 103 0.2718
N-D2 43 11 54 0.2037
N-D3 0 94 94 1.0000
N-D12 43 11 54 0.2037
N-D13 0 14 14 1.0000
N-D123 3 15 18 0.8333
D1-D12 104 59 163 0.3620
D1-D13 0 13 13 1.0000
D1-D123 3 49 52 0.9423
D2-D23 0 26 26 1.0000
D2-D12 98 54 152 0.3553
D2-D123 7 64 71 0.9014
D3-D13 14 0 14 0.0000
D3-D23 1 0 1 0.0000
D3-D123 7 0 7 0.0000
D12-D123 218 318 536 0.5933
D13-D123 5 1 6 0.1667
D23-D123 2 2 4 0.5000
D12*-D123 1 24 25 0.9600
D12**-D123 1 10 11 0.9091
*Participants positive for DENV-1 or DENV-1/-2 in first sample.
**Participants positive for DENV-2 or DENV-1/-2 in first sample. In both cases
participants did not have DENV-3 above thresholds levels in samples previous
to seroconversion. For incidence calculations these individuals were
considered monotypic.
N = negative, D1 =DENV-1, D2 =DENV-2, D3 =DENV-3, D12 =DENV-1 and -2,
D13 =DENV-1 and -3, D23 =DENV-2 and -3, D123 =DENV-1, -2 and -3,
D12* =DENV-1 or DENV-1 and -2, D12**=DENV-2 or DENV-1 and -2.
doi:10.1371/journal.pntd.0000670.t001
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seroconversion or an elevated IgM titer of$1:400 were counted as
seroconversions in all incidence calculations, even if pre- and/or
post-sample PRNT data was not available or discordant, whereas
individuals with an elevated IgM titer of 1:100 or IgG serology
were only included for incidence calculations if confirmatory
PRNT data was available.
IgM-capture ELISA. Dengue-specific IgM antibody titers
were determined by an IgM-capture ELISA adapted from
published protocols [28]. Briefly, plates (96-well format) were
coated with anti-human IgM antibody to capture participant IgM
antibody. Virus-specific IgM was detected by the addition of
dengue viral antigen, followed by virus-specific hyperimmune
ascitic fluid and horseradish peroxidase (HRP)-labeled anti-mouse
IgG. Following the addition of colorimetric substrate, plates were
read at 410 nm. All acute- and convalescent-phase samples were
initially screened at a 1:100 dilution. Samples exceeding the
reference cut-off value, calculated as the mean of seven antibody-
negative samples plus three standard deviations, were considered
IgM antibody-positive. Positive samples were subsequently re-
tested at four-fold serial dilutions to determine end-point antibody
titers.
IgG-ELISA. Dengue-specific IgG titers were determined by
an IgG ELISA adapted from Ansari et al. [29]. Plates (96-well
format) were coated with DENV antigen (cocktail of serotypes 1,
2, 3 & 4) produced from infected Vero cell culture lysates or
uninfected cell lysates as controls. Aliquots of diluted participant’s
serum samples (1:100) were added to two dengue antigen coated
wells and to two control wells. After addition of HRP-conjugated
mouse anti-human IgG, OD values were recorded at 410 nm.
Adjusted OD values were calculated by subtracting the OD of the
uninfected antigen coated well from that of the corresponding viral
antigen coated well. The cutoff OD value for determining
antibody positivity was calculated as the mean adjusted OD plus
3 standard deviations of antibody negative control sera.
RT-PCR. Viral RNA was prepared from 140 ml of each sera
sample using QIAamp Viral RNA Mini Kits following the
manufacturer’s instructions (Qiagen Inc., Valencia, CA 91355).
Nested DENV RT-PCR was performed following the protocol of
Lanciotti et al. [30] on serum samples for dengue viral RNA
detection.
Virus isolation. Isolation of DENV serotypes was attempted
on all acute serum specimens. Using standard virological
techniques, cell cultures (C6/36 and Vero cells) were inoculated
with serum and monitored for cytopathic effects. All cells
inoculated for virus isolation were tested by immunofluorescence
assay using DENV serotype-specific monoclonal antibodies
whether or not the cells show cytopathic effects.
Statistical Analyses
Proportions were compared using a chi-square test using the
FREQ procedure in SAS (SAS Version 8, 1999, SAS Institute
Inc., Cary, NC.) with statistical significance assessed at an alpha
level of 0.05. We calculated seroprevalence rates from serostatus in
the first blood sample of all participants enrolled through
September 1999 when an active cohort of 2,400 participants
was achieved as interpreted through examination of complete
serological profiles (see Interpretation of PRNT results above).
Incidence rate calculations. Except for clinically apparent
cases, we were unable to identify the time of infection between
paired blood draws taken at ca. 6 month intervals. We thus
calculated seroincidence rates and 95% CI for 10 time periods
between January 1999 and February 2005 assuming that infection
occurred on the mid-date of the monitoring interval. Thus the
incidence rate for a time interval was the total number of
seroconversions with mid-dates occurring within the time period
(numerator) divided by the sum of person-days contributed each
participant during the time period (denominator). Serotype-
specific incidence rates only included person-days of participants
who were susceptible to that serotype at the start of the monitoring
interval. Calculations assuming that infections occurred at the end
of each monitoring interval were qualitatively and quantitatively
similar to those calculated assuming that infection occurred on the
mid-date of the interval; only a temporal shift was observed
(Tables S3, S4, S5). Maps and GIS information were managed
using Arc-View 3.2 (ESRI, Redlands, CA).
Results
Between February 21, 1999 and February 12, 2005 to maintain
an active cohort of 2,400 study participants, a total of 4,586
participants were enrolled in the study. Seventy-five percent were
enrolled between February 1999 and March 2000 (Figure 1, Table
S1). Of all participants, 683 (14.9%) individuals were lost to follow
up after providing a single baseline sample, whereas the remaining
3,903 (85.1%) participants provided between 2 and 14 samples
(Figure 1). Fifty-two percent (n = 2,383) and 31.5% (n = 1,445) of
the participants provided $4 and $7 blood samples, respectively.
The majority of participants (77.9%; n = 3,571) were younger
than 18 years of age. Females were more common than males,
representing 57.5% (n = 2,637) of the overall study population.
Among adult participants, female participation (75.0%) was
significantly higher than for males (P,0.0001). Study participants
providing single or multiple blood draws had a comparable
distribution by gender (P = 0.7), but the proportion of adult
participants among those lost to follow up after providing a single
sample was slightly higher than among participants who provided
multiple samples (P,0.003, Figure 2). The ages of enrollees were
evenly distributed among school age children (77.9% of cohort
population) and adults except for the .60 years group and was
consistent between participants who provided multiple samples
and those dropping out after a single sample (P = 0.17, Figure 2).
Participants were recruited from 36 to 60 city blocks in each of 8
geographic zones (Table 2). The proportion of participants leaving
the study after a single blood draw ranged from 10.6 to 19.9%
(P,0.0001) among the 8 zones.
School-based surveillance was carried out on a subset of 1,000–
1,180 cohort participants each year (Table S6) between the ages of
5 and 18, with slightly more female (53.4%) than male enrollees.
Figure 2. Number of participants enrolled in a 1999–2005
cohort by age. The percentage of enrollees providing .1 blood
sample was consistent among age groups (78–87%, P= 0.17).
doi:10.1371/journal.pntd.0000670.g002
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PRNT Assay
Although the time interval between blood samples was relatively
long (,6 mo), we observed cross-reactive antibody in the first and
sometimes second post-conversion blood samples, which became
specific in subsequent samples (e.g. [N-N-D12-D1-D1], see Table 1
for sequence abbreviations). The rate of apparent cross-reaction
was similar for primary (18.8%, 29/154) and secondary infections
(23.9%, 33/138).
Correction factors for all observed infection sequences are
shown in Table 1. Of the 22 participants whose baseline PRNT
sample showed evidence of monotypic infection with DENV-3
followed by an apparent infection to either DENV-1 or DENV-2,
none had supportive PRNT results in subsequent samples
(correction factor = 0 in Table 1). Overall, profiles indicating
seroconversion were reliable for new DENV-3 infections (correc-
tion factor.0.90), but less so for new DENV-1 and DENV-2
infections (correction factor,0.37). Correction factors decreased
for participants with a polytypic pre-conversion status, but these
seroconversions held up .50% of the time for new DENV-3
infections. In a number of cases, pre-conversion blood samples
presented a % reduction that was between 1 and 10% below the
cutoff, followed by a 20% increase in the subsequent sample. In
other instances, serology suggested infection with DENV-3, only to
fall off in subsequent samples. According to our criteria, none of
these cases would be considered unequivocal seroconversions;
although they could be true seroconversions our assay was not
sensitive enough to detect them. Estimates of incidence with and
without these possible seroconversions did not have any significant
effect on the outcome (see Tables S3, S4, S5).
Seroprevalence
Overall, we were able to interpret baseline serostatus for 99.9%
of study participants. For all participants enrolled before October
1999 (n = 2,527) only 19.7% (n = 498) did not have serological
evidence of prior dengue infection. Approximately half the
participants had DENV NtAbs against both DENV-1 and
DENV-2 (1,292, 51.1%) at the baseline sampling period of the
study; 366 (14.5%) and 368 (14.6%) had monotypic NtAbs to
DENV-1 and DENV-2, respectively. DENV NtAbs were observed
at the same rate in participants providing a single (286 of 350,
81.7%) or multiple (1,740 of 2,174, 80.0%) blood draws
(P = 0.4642).
Prevalence of DENV NtAbs was higher among females (1,170
of 1,424, 82.2%) than males (856 of 1,100, 77.8%; P = 0.0065) and
increased with age. Of adults ($18 years) prevalence was 91.2%
(423 of 464), while among children (,18) it was 77.8% (1,603 of
2,060; P,0.0001). Over half of the youngest group (5 year-olds)
presented evidence of DENV NtAbs (56.1%) and this proportion
increased steadily with age with more than 87% of the participants
$14 year-olds showing a history of infection (Figure 3, P,0.0001).
DENV seroprevalence rates varied geographically (Figure 4). Age-
adjusted rates ranged from 67.1 to 89.9% (P,0.0001) with lower
rates in zones (BG, PT, TA) where some households were located
in river-front areas that are seasonally flooded.
Seroincidence
Of the 3, 903 participants who provided at least 2 blood
samples, 2,542 (65.1%) had no change in their serostatus
compared to baseline over the observation period (Table 3). A
total of 1,414 DENV seroconversions occurred during the study
period among 1,347 participants (34.5% of the cohort); 1,281
participants showed evidence of infection with a single serotype, 65
to 2 serotypes, and 1 to 3 serotypes. Of these 1,414 seroconver-
sions, 585 (41.4%) were in the final blood sample, which cannot be
conclusively determined to be true seroconversions, and 62 (1.6%)
were ambiguous (see PRNT, above) (Table 4 and S2). Complete
result profiles from 14 participants were excluded because they
could not be interpreted. The majority of infections were
secondary (75.7%, Table 4). Prior to invasion by DENV-3 the
ratio of the incidence of primary to secondary infections was less
Table 2. Number of participants enrolled in 1999–2005 cohort by geographic zone.
Zone No. Enrolled No. Blocks
Average No. persons
per block (SE)/Range
% Enrollees with .1
blood sample
% Enrollees with anti-DENV
antibody during 1999 baseline
1 sample .1 sample
BG 559 40 14.0 (2.6)/1-70 80.1 82.0 65.6
IQ 406 36 11.3 (2.7)/1-98 88.2 84.6 80.8
MC 485 53 9.2 (0.9)/1-30 85.6 78.0 87.1
MY 639 60 10.7 (1.4)/1-52 89.4 96.6 90.2
PT 479 48 10.0 (1.3)/1-34 86.0 83.3 72.4
PU 617 50 12.3 (1.6)/1-46 80.1 83.8 84.8
SA 499 51 9.8 (1.5)/1-42 81.2 68.2 87.0
TA 902 54 16.7 (2.1)/1-87 88.7 83.9 69.8
doi:10.1371/journal.pntd.0000670.t002
Figure 3. Age-specific seroprevalence rates for participants
enrolled in the longitudinal cohort between February and
September 1999.
doi:10.1371/journal.pntd.0000670.g003
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than two –fold, then increased to more than five-fold through the
peak of epidemic transmission (Table 5). By 2004, the rate of
dengue infection in primary and secondary infections was nearly
equal. DENV-3 was responsible for 58.4% of infections and most
likely responsible for an additional 18.8% (cross reactive responses
that included DENV-3 antibody) of all the DENV infections
observed (Table 4). The exact infecting serotype could not be
identified in 24.9% of the primary infections (see Table 4; N-D12,
N-D13, N-D23, N-D123) and 17.9% of the secondary infections
(see Table 4; D3-D123, D2-D123, D1-D123).
Figure 4. Seroprevalence rates for cohort participants enrolled between February and September 1999 in 8 geographic zones in
Iquitos, Peru.
doi:10.1371/journal.pntd.0000670.g004
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Among the febrile children captured through active school
absence monitoring, 73 confirmed DENV infections were
identified; 20 by virus isolation, 14 by RT-PCR, and 39 by IgM
serology (Table 6). Another 42 participants had symptoms
consistent with DF and PRNT evidence for a seroconversion
during the monitoring interval of their febrile episode. Of these 11
with an IgM antibody titer of 1:100 and 3 with a 4-fold rise in anti-
DENV IgG antibody titer between acute and convalescent
samples were included in the calculation of symptomatic dengue
infections. In total, we identified 11 DENV-1 cases (7 primary, 4
monotypic to polytypic), 2 DENV-2 cases (1 primary, 1 monotypic
to polytypic), and 74 DENV-3 cases (22 primary, 20 monotypic to
polytypic, 32 DENV-1/-2 to DENV-1/-2/-3). For 5 primary and
23 secondary infections the infecting serotype could not be
identified.
Temporal Trends
During the first 15 months of the study, DENV-1 and DENV-2
co-circulated at low infection rates, with approximately 2 and 6
infections per 100 people per year in the entire population and
susceptible population, respectively (Table 7). DENV-3 appears to
have been introduced into Iquitos sometime in 2001. The first
DENV-3 isolate was recovered from a DF case on December 7,
2001 [13](TJK, unpublished results). We detected only 2 clinical
DENV-3 cases in our school surveillance study prior to January
2002. In addition, 2 febrile participants detected in July 2001 had
no detectable IgM response, but did show a 4-fold rise in IgG titer.
Both had NtAb to DENV-3 in 2002 PRNT results. Examination
of PRNT antibody results indicates possible DENV-3 transmission
at least 5–6 months earlier than the first isolate. First evidence of
DENV-3 transmission was in a sample taken from a 5 year-old
female whose last PRNT sample taken on May 27, 2001 indicated
seroconversion to this serotype, but no subsequent samples were
taken to confirm this result. The next earliest indications of
transmission were in samples taken July 24 from a 12 year-old
male and July 27 from a 20 year-old female. The previous blood
samples taken at the end of 2000 from both of these participants
were negative for DENV antibody, thus indicating that infection
took place sometime between December 2000 and late July 2001.
During the first trimester of 2002 we observed increased
DENV-1 and DENV-3 transmission, with a steady increase in the
incidence of DENV-3 infection from12.9 to 29.6 seroconversions
per 100 p-years at risk between the first and last trimester of 2002,
corresponding to a major dengue outbreak in Iquitos. Transmis-
sion rates of DENV-3 decreased steadily through the end of
August 2003 when our community-based study ended. A subset of
Table 3. Summary of serological results for 3,903 participants (15,780 monitoring intervals) providing $2 blood samples in
longitudinal cohort study, Iquitos, Peru 1999–2005.
Status No. % Intervals
Total Consistenta False (+) False (2) 1 intervald
1b 2c
No Seroconversion
Negative N-N 585 23.0 2833 2435 (86.0%) 14.0% 1.4%
Monotypic 620 24.4 3326
D1-D1 285 11.2 1429 1058 (74.0%) 20.6% 2.0% 5.3%
D2-D2 295 11.6 1696 1290 (76.1%) 17.9% 1.2% 6.1%
D3-D3 40 1.6 201 124 (61.7%) 34.3% 5.4% 4.0%
Polytypic 1337 52.6 8066
D12-D12 1144 45.0 6393 5127 (80.2%) 8.0% 1.9% 11.8%
D13-D13 8 0.3 61 16 (26.2%) 49.2% 8.1% 24.6%
D23-D23 7 0.3 53 10 (20.4%) 77.6% 22.4% 10.2%
D123-D123 97 3.8 936 739 (79.0%) - 1.9% 21.0%
D12-D12 57 2.2 443 421 (95.0%) 2.0% 0.2% 2.9%
D12-D12 24 0.9 184 166 (90.2%) 2.2% 1.9% 7.6%
Total 2542 65.1 14229 11386 (80.0%)
Seroconversions
Single 1281 32.8 1281
Double 65 1.7 130
Triple 1 0.03 3
Total 1347 34.5 1414
Serostatus of each study subject (No.) either remained consistent for all monitoring intervals throughout their participation (No seroconversion) or showed serological
evidence of 1, 2 or 3 DENV infections (seroconversions). Top panel shows the number of participants and monitoring intervals where no serological changes were
observed, demonstrating the percentage of sampling intervals where antibodies to other DENV serotypes were observed (false+/cross-reactive antibodies) for 1 or 2
monitoring intervals or where titers fell below threshold values for a single interval. Lower panel shows the number of seroconversions observed.
aAll PRNT results were the same, e.g., [N-N-N or N-N-N-N or D1-D1-D1-D1 or D12-D12-D12-D12-D12].
be.g. [N-N-D2-N-N-N or D1-D12-D1-D1-D1].
ce.g. [N-D2-D2-N-N-N or D2-D12-D12-D2-D2].
de.g. [D2-D2-N-D2-D2 or D12-D12-D1-D12-D12].
doi:10.1371/journal.pntd.0000670.t003
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our study cohort was followed in school surveillance from
September 2003 through February 2005. In this later group
seroconversion rates were consistent with the May–August 2003
trimester through May 2004 but increased dramatically in the last
half of 2004, which corresponded to another dengue outbreak.
When seroconversion rates were calculated for the subset of the
longitudinal cohort enrolled in the school surveillance program,
they were similar to those for the entire cohort, except for May to
December 2002 when seroconversion rates appeared about 10
SCs per100 p-years less in the school cohort when adjusted for the
susceptibility patterns of the population (Table 8, Figure 5, pink
line compared to green). Population-based seroconversion rates
were nearly identical. Incidence of symptomatic DF cases in the
school cohort was significantly lower than the seroconversion rate
in the sample population, ranging from 0.6 to 13 cases per 100 p-
years (Figure 5).
The inapparent to apparent dengue case ratio varied over time
(Figure 5). Prior to June 2001, when only DENV-1 and -2 were
circulating, the ratio was low (approximately 1:1), but increased
rather dramatically in the last half of 2001, when DENV-3 was
most likely introduced. In 2002, during the height of transmission,
ratios ranged from 2.6–5.3:1.
Geographical Patterns
Rates of DENV seroconversion varied significantly among
geographical zones of the city (Figure 6). When calculated for the
entire study period seroconversions (SCs) were highest in the two
northeastern zones (MY and PU) and one central zone (MC)
(mean 28.6–31.5 SCs per 100 p-years at risk), followed by another
central zone of IQ (24.5 SCs per 100 p-years at risk). Based on
baseline seroprevalence rates, SA had less activity (20.5 SCs per
100 p-years at risk) and TA had more DENV activity than
expected (20.4 SC per100 p-years at risk). DENV infection rates
were lowest in BG and PT. Temporal patterns of transmission
varied by zone. For example, for the period from January 1999
through March 2000 SC rates were similar between DENV-1 and
-2, with more activity in TA (13.2 SCs per100 p-years) than in the
other zones (1.5–5.8 SCs per100 p-years).
The first observed seroconversions to DENV-3 occurred in IQ,
MY, and TA (Figure 4), suggesting virus spread rapidly
throughout the city. Indeed, early infections of DENV-3 were
distributed across all 8 geographic zones, although most cases
occurred in MY and IQ during the first trimester of 2002.
Transmission lagged in MC and PU, with SC rates peaking during
the September–December 2002 trimester. BG lagged even further,
with the highest transmission rates observed during the January–
April 2003 time period.
Discussion
Results from our longitudinal cohort reveal details of dengue
dynamics during the transition from interepidemic to epidemic
transmission that can help inform increasingly effective surveil-
lance and disease prevention programs. Observations reported
here set the stage for subsequent publications addressing the
quantitative relationship between Ae. aegypti population densities
and DENV transmission across periods of different forces of
infection with the long-term goal of identifying entomological
transmission thresholds [31] and examining age-specific hetero-
geneities in DENV transmission, the impact of vector and vaccine
interventions, and heterogeneities (spatial and temporal) in
transmission patterns. We begin by reviewing overall patterns of
infection followed by a discussion of the consequences of invasion
of a locally novel serotype.
In 1999, at the onset of the study, we detected baseline
seroprevalence rates across DENV serotypes in Iquitos that ranged
from 56% in 5 year olds to 87–94% in subjects $14 years old.
Among school age children there appeared to have been greater
than a 2-fold rise in cumulative infections since 1992 [12]. Our
seroprevalence rates are consistent with those observed in SE Asia
[21,32,33] and Indonesia [22], although it appears that seroprev-
alence increases more slowly with age in Iquitos. Possible
explanations for this observation include: (1) the sequential nature
of serotype introduction into Iquitos, (2) relatively low vector
Table 4. Summary of 1,414 seroconversions detected among
1999–2005 longitudinal cohort participants by PRNT in
Iquitos, Peru.
Status Seroconversions
Unequivocal Putativea
No. % No. %
1u Infections N-D1 23 1.63 33 2.33
N-D2 10 0.71 8 0.57
N-D3 94b 6.65 60 4.24
N-D12 11 0.78 24 1.70
N-D13 14 0.99 23 1.63
N-D23 2 0.14 3 0.21
N-D123 15 1.06 17 1.20
ALL 1u 169 11.95 168 11.88
2u Infections DV-1 D2-D12 45 3.18 28 1.98
D3-D13 0 0.00 7 0.50
D23-D123 2 0.07 4 0.28
ALL D1 47 3.89 39 2.76
DV-2 D1-D12 54 3.82 45 3.18
D3-D23 0 0.00 1 0.07
D13-D123 1 0.07 0 0.00
ALL D2 55 3.89 46 3.25
DV-3 D1-D13 13 0.92 10 0.71
D2-D23 26 1.84 8 0.57
D12-D123 318c 22.49 209d 14.78
D12-D123 24 1.70 14 0.99
D12-D123 8 0.57 6 0.42
ALL D3 389 27.51 247 17.47
DV-1 or DV-2 D3-D123 0 0.00 6 0.42
DV-1 or DV-3 D2-D123 63e 4.46 35 2.48
DV-2 or DV-3 D1-D123 44f 3.11 44 3.11
ALL 2u 598 42.29 417 29.49
TOTAL 767 54.24 585 41.37
aSeroconversion occurring in final pair of samples from a participant (eg. [N-N-
N-D1] or [D1-D1-D1-D12]). For incidence calculations numbers will be
multiplied by a correction factor calculated based the proportion of specific
pair profiles (i.e. N to D1, D1 to D12, D12 to D123) observed that are
maintained in subsequent samples (ie., N-D1-D1 or D1-D12-D12) versus those
that represent false+ results (i.e. N-D1-N or D1-D12-D1).
b1 with 2nd sample 8/12/2001.
c14 participants with 2nd sample dates in 2001 (July = 3; October = 6;
November = 1; December = 4 ).
d9 participants with 2nd sample in 2001 (August = 1; October = 2; December = 6).
e2 participants with 2nd samples on 5/27/01 and 10/26/01.
f1 participant with 2nd sample 10/25/2001.
doi:10.1371/journal.pntd.0000670.t004
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abundance that is associated with a relatively low force of
infection, and 3) high rates of migration into and out of the city
from remote river communities throughout the Amazon Basin
where DENV transmission is minimal. In comparison to other
parts of Latin America, seroprevalence rates in Iquitos were lower
than those reported in Nicaragua [34] but similar (or slightly
higher) than Salvador, Brazil [35] and Maracay, Venezuela [24].
Overall 34.5% of our study population seroconverted to at least
1 DENV serotype during the course of the study. Prior to the
introduction of DENV-3, 6–8 of every 100 susceptible individuals
(2–2.6 per 100 in the study population) per year had a DENV
infection. This is consistent with observations in Kamphaeng Phet,
Thailand [36], where transmission of all 4 DENV serotypes was
recorded over 3 years with marked spatial and temporal variation
Table 5. Seroincidence of primary and secondary infections for all DENV serotypes between February 1999–February 2005.
Date Primary Infections Secondary Infections
Serotype-Adjusted Population-based Serotype-Adjusted Population-based
2/99–3/00 2.73 (2.52–2.93) 0.53 (0.51–0.55) 4.34 (4.17–4.51) 1.47 (1.42–1.53)
4/00–5/01 3.48 (3.25–3.71) 0.66 (0.64–0.68) 6.38 (6.17–6.59) 1.96 (1.90–2.02)
6/01–12/01 3.90 (3.47–4.33) 0.69 (0.66–0.72) 23.04 (21.86–24.22) 4.80 (4.58–5.02)
1/02–4/02 12.11 (10.43–13.78) 2.68 (2.51–2.85) 63.95 (59.30–68.59) 17.37 (16.27–18.48)
5/02–8/02 17.77 (15.64–19.89) 3.52 (3.35–3.70) 147.59 (139.00–156.18) 34.28 (32.55–36.00)
9/02–12/02 39.89 (35.45–44.34) 8.66 (8.21–9.10) 110.89 (103.62–118.16) 30.27 (28.72–31.82)
1/03–4/03 14.11 (12.21–16.00) 2.79 (2.62–2.95) 36.67 (33.69–39.65) 11.35 (10.67–12.03)
5/03–8/03 3.33 (0.07–6.60) 0.48 (0.34–0.63) 17.54 (10.52–24.56) 4.95 (3.48–6.41)
9/03–5/04 5.68 (4.42–6.94) 0.92 (0.83–1.01) 20.87 (18.17–23.56) 5.84 (5.28–6.40)
8/04–2/05 23.54 (19.96–27.12) 7.79 (7.10–8.48) 28.34 (24.79–31.90) 14.18 (12.92–15.44)
Bolded rows include school-based component only. Seroincidence rates were calculated under the assumption that infection occurred at the midpoint of the sampling
interval. Incidence rates were adjusted based on susceptibility patterns (sero-type adjusted) and for the entire study population (population-based).
doi:10.1371/journal.pntd.0000670.t005
Table 6. Summary of dengue cases identified through febrile case surveillance in school-based cohort between June 2000 and
December 2004.
Status Diagnostic Assay
Viral Detection IgM SC Elevated IgMb IgG SCc Clinical w/PRNTd Total
DENV-1 1u 2 2 - - 3 7
2u 1 - 1 - 2 4
DENV-2 1u - 1 - - - 1
2u - 1 - - - 1
DENV-3 1u 9 2 9 - 2 22
2u
DENV-1/-3 1u2u -22 -10 17 -3a -10 152
- 3 3 - 2 8
DENV-2/-3 1u - - - - - -
2u - 3 1 - - 4
DENV-1/-2/-3 1u - 2 - - 1 3
2u - - - - - -
Unknown 1u - - 1 - - 2
2u - - 1 7 - 8
UK - 1 1 1 - 3
Total 1u 11 7 2 - 6 35
2u 23 17 13 10 14 77
UK - 1 1 1 - 3
aAll 3 individuals were febrile in late July 2001.
bIncludes 11 participants with an elevated IgM titer of 1:100 with supporting PRNT data indicating seroconversion during sampling interval.
c3 of 10 participants with supporting PRNT data indicating seroconversion were included for incidence calculation.
dNone in this category was included for incidence calculations.
doi:10.1371/journal.pntd.0000670.t006
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[37]. It is also similar to published rates from Nicaragua [34]
where only two serotypes were circulating and seroprevalence
rates for existing serotypes were extremely high. In both the
Iquitos and Managua situations, transmission was observed despite
high prevalence of antibodies against multiple serotypes of DENV.
With the virgin-soil epidemic of DENV-3, seroconversion rates
increased up to 90 per 100 p-years. School surveillance indicated
infection rates increased each trimester of 2002 to a maximum
during September–December. DENV-3 seroconversion rates
during 2002 were consistent with those previously reported from
Iquitos during outbreaks of DENV-1 in 1992–1993 (55%) and
DENV-2 in 1993–1995 (86%; [7,12]). Rates this high have also
been reported from Brazil (annual incidence of 70.6%; [35]) and
during an outbreak in Bangkok, Thailand (87%; [32]).
The introduction of DENV-3 into Iquitos can be divided into 3
distinct periods: (1) amplification, characterized by serological
evidence of infection with the novel serotype and a paucity of
clinically apparent cases detected, (2) replacement, characterized
by the appearance of the first confirmed clinical cases and a rise in
activity of previously circulating serotypes (DENV-1 in this case)
concomitantly with cases of the novel serotype, and (3) epidemic,
where the novel serotype dominated and caused an outbreak of
clinical disease.
Amplification
We estimate that DENV-3 was introduced into Iquitos between
May–July 2001, and then transmission was amplified during the
last trimester of that year when unusually high Ae. aegypti
population densities were observed [17]. We identified 27
participants who had evidence of a DENV infection between
May and December 2001 and 2 febrile participants were detected
in July 2001. DENV-1 was also circulating at this time and could
have been the cause of some of these seroconversions, all of which
appeared polytypic. None of these individuals showed evidence of
DENV-3 NtAbs prior to this time and subsequent blood samples
indicated consistent positive DENV-3 results. Together these cases
point to low level serotype 3 activity occurring at least 5–6 month
and up to a year prior to our first isolation of DENV-3 during
December 2001, despite rigorous virological surveillance. Gubler
[38] described a latent period of this duration from introduction to
detection of overt disease, but to the best of our knowledge this is
the first empirical evidence for this phenomenon.
Replacement
Virus isolation data from clinics in Iquitos indicated that DENV
transmission started to increase in late 2001 and early 2002, but
was predominantly DENV-1. By March 2002, DENV-3 virus
isolates predominated. In addition there were 2 isolates of the
Asian serotype of DENV-2 in early 2002 (Kochel et al.
unpublished) and presentation of the first clear clinical cases of
DF were observed in our school cohort. The initial increase in
DENV-1 transmission supports the idea that entomological and
environmental conditions had become favorable for virus
transmission. DENV-3 had been present in northwestern Peru
since 2000 and Guayaquil, Ecuador since 1999 [13]. There was
also virological evidence of DENV-3 circulation in 2001 in
Pucallpa and Yarinacocha, both cities located on a major route of
river travel and commerce to the south of Iquitos in the Amazon
Basin and connected by road to Lima, the capital of Peru [39]. We
speculate that the relatively rapid replacement of DENV-1 with
DENV-3 and the failure to see continued transmission of Asian
DENV-2 can be explained by short term cross protection to
heterologous serotypes by recent DENV infections. Nearly the
entire Iquitos population was susceptible to DENV-3, whereas
seroprevalence rates indicated high rates of previous infection with
DENV-1 and DENV-2, and upon introduction of DENV-3 the
low percentage of people susceptible to DENV-1 or DENV-2
would be even further reduced by the cross-protective response
following DENV-3 infection. A similar pattern was observed
recently with the 2008 introduction of DENV-4 into Iquitos [14].
Epidemic
Infection rates steadily increased throughout 2002 to a peak
level of 89 SC per 100 p-years, and rates of clinically apparent
Figure 5. Comparison of DENV seroconversion and case incidence rates between January 1999 and February 2005. Incidence rates
are expressed as cases or seroconversions per 100 person-years at risk. Symptomatic-to-asymptomatic case ratios were calculated from incidence of
active dengue cases within the School surveillance program (yellow line) compared with overall seroconversion rates within susceptible (purple line)
or the entire school cohort (pink line). The ratios are shown above the curves for each time period for the susceptible (purple) and entire (pink)
population. Seroconversion rates assuming infection took place at the mid-point (green) or end-point (blue) of the monitoring interval are shown for
the entire longitudinal cohort calculated for both the susceptible (dark) and entire (light) populations.
doi:10.1371/journal.pntd.0000670.g005
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disease increased from 13 cases/100 p-years to 19 cases/100 p-
years at risk. Transmission decreased dramatically after a city-wide
vector intervention based around household ultra low volume
adulticide applications and larvicide treatment of Ae. aegypti-
producing containers (Morrison et al unpublished). In 2004,
another outbreak of DF and the first documented cases (7) of DHF
were observed. Although no DHF cases were observed in our
school surveillance study, reports from local health officials
indicated that severe cases of severe illness were observed only
during periods of intense transmission at the end of 2002 and
again in 2004 (Sihuincha, personal communication) indicating
that, in Iquitos, slowing the force of infection with an effective
vector control program had beneficial public health consequences.
The spatial evolution of the epidemic illustrated that dengue
viruses spread rapidly and moved through different areas of the
city at different times. Clinically apparent illness providing the
earliest evidence of transmission indicated that infected people
were scattered across the city, implicating human movement in the
dispersal of virus because flying infected Ae. aegypti would not move
those distances in that short a time period [40]. Within geographic
zones, patterns appeared to reflect the suitability of local
conditions for transmission of pathogen. For instance, the timing
of peak transmission varied from as early as the January–April
2002 trimester to as late as the same trimester in 2003. In addition,
the neighborhood whose peak transmission occurred last in 2003
also had the lowest seroprevalence rates at baseline, which we
attribute to consistently lower Ae. aegypti indices [17]. Spatial
patterns in seroincidence did not follow seroprevalence patterns
prior to 2001, but did afterwards. This indicates these areas were
of high risk, but herd immunity probably prevented higher
transmission rates.
An important observation is the fluctuation in ratio of apparent
to inapparent case rates observed over the course of the study.
Prior to June 2001 the apparent to inapparent ratio was
comparable to that reported by Endy et al. [36] in Thailand,
before increasing to 5:1 during the initiation of the DENV-3
outbreak (Figure 5). In 2003 the ratio increased steadily to 40:1 for
the period between September 2003–May 2004 and 24:1 during
the last half of 2004 when significant clinical disease was observed.
This higher ratio of asymptomatic or subclinical cases after May
2003 may in part be due to a decrease in force of infection owing
to vector control interventions. After August 2003, additional
Figure 6. Seroincidence rates from January 1999–February 2005 in 8 geographic zones in Iquitos, Peru. Rates are expressed in 100
person-years at risk with the overall rate for the entire study period shown in the upper left portion of each figure and the zones in the upper right.
Rates were calculated for same time periods shown in Table 7.
doi:10.1371/journal.pntd.0000670.g006
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individuals were recruited into the school surveillance study and
the community-based part of the study was discontinued. It is
possible that our methodological shift affected the efficiency of our
surveillance, but the dramatic shift in incidence of apparent
dengue cases is difficult to explain except through positive impact
of herd immunity.
Independent of the time interval monitored, infection rates
among individuals who had been previously infected with DENV
(secondary infections) always exceeded rates of primary infections.
The higher incidence of secondary versus primary infections was
least dramatic prior to the introduction of DENV-3 and during
June 2004–February 2005 after that serotype had been circulating
for 2 years. It was during these periods that our observations were
consistent with previously published studies [21,22,33,35]. During
epidemic transmission in 2002, however, the secondary infection
rate exceeded that of primary by 5–8 fold, decreasing in 2003 to
3–5-fold until June 2004 when the rates of primary and secondary
infections were nearly equal. This indicates that many people in
the population have consistent exposure over time and that
seroprevalence patterns can be informative for establishing
surveillance zones of consistently low versus high entomological
risk. For example, in the geographic zone MY, seroprevalence
patterns indicated high rates of historical transmission which also
corresponded to some of the highest entomological indices in
Iquitos [17]. Although pre-invasion seroincidence rates were
relatively low in this zone, post-invasion incidence patterns
indicate that transmission increased rapidly here prior to other
areas of the city. It is worth noting that the higher incidence rates
among participants who had been previously infected by a
heterologous serotype, reliance on a serologically naı¨ve population
for longitudinal studies would underestimate overall DENV
activity and would, thus, be inappropriate for early detection
(i.e., sentinels).
A serious impediment to large population-based longitudinal
studies on dengue has been logistical and technological barriers
associated with serological testing [41]. In our hands, the PRNT,
although expensive and labor intensive, provided a reliable way to
measure seroconversion rates in a large population. For long term
studies the PRNT permits monitoring of cohort participants at
longer time intervals (6 months to 1 year) than alternative ELISA
or HAI-based assays that require shorter intervals (,3 months) to
identify seroconversions. The PRNT provides serotype-specific
information, which the other assays do not, that is critical for
assessing the risk of populations for epidemic transmission of a
novel serotype. PRNT results become more informative as the
number of blood samples per participant increases because
multiple samples (preferably .3) provide a ‘‘serological profile’’
that can corroborate observations made from a single monitoring
interval. For example, when at least one sample was available after
the interval where a seroconversion occurred, the infecting
serotype could be determined in 75.1% (127/169) of primary
and 77.4% (345/446) of secondary infections. For individuals who
had no change, 80% of the intervals monitored had consistent
PRNT results; 11.7% and 8.3% showed transitory ‘‘false’’ positive
and ‘‘false’’ negative results, respectively. Moreover, data from the
entire study population can be used to derive correction factors to
improve estimates of seroconversions in persons who have no
samples taken after the seroconversion interval. We recommend
that cutoff values be established empirically using serum samples
with known infection histories. Responses may vary based on the
local history of DENV serotype circulation and the genetic
background of the resident populations [8,24]. Four serial
dilutions rather than the two used in this study improves
interpretation of the portion of the human population with
ambiguous responses [24]. A challenge to the application of
PRNT results in a population-based study is that there remain
important knowledge gaps in expected NtAb responses to virus
challenges with homologous serotypes and related Flavivirus
species, cross-reaction patterns among the four DENV serotypes,
and how long NtAb titers remain above cutoff values for what
proportion of the population.
Our results show a strong similarity between baseline seroprev-
alence patterns and seroincidence patterns the year following the
introduction of a novel dengue serotype. Herd immunity clearly
has a profound impact on seroincidence patterns under periods of
endemic transmission. In locations like Iquitos, where there was
not hyperendemic transmission of all 4 serotypes, surveillance and
control programs must consider separate strategies for (1)
managing transmission of existing serotypes and (2) preparing
for and dealing with either the introduction of novel serotype/
genotype or analogous situations where immunity in the human
population is low. The major challenge remains early detection of
and effective response to novel virus activity. Our experience in
Iquitos indicates that establishment of a new serotype requires a
short period where environmental conditions are favorable for
amplification of virus (high adult Ae. aegypti populations and
ambient temperatures) and that these characteristics can be
incorporated into early warning systems. The lag time from
introduction to epidemic transmission that we estimated for
DENV-3 in Iquitos (6–12 months) and knowledge of spatially
explicit areas of elevated risk (Maynas) should be considered for
targeting more effective application of limited resources for dengue
prevention.
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